Artwork

Content provided by Life Sciences WA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Life Sciences WA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Emerging opportunities in medicinal cannabis and psychedelics. Michael Winlo - Emyria Ltd & Fleta Solomon - Little Green Pharma

58:11
 
Share
 

Manage episode 397108888 series 3427899
Content provided by Life Sciences WA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Life Sciences WA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of the LSWA podcast, host Tracey Wilkinson interviews Fleta Solomon and Michael Winlo, two experts in the field of psychedelic-assisted therapy and medical cannabis. They discuss the potential of these treatments to revolutionise mental health care and provide a more holistic approach to patient care.

The conversation begins with a focus on the use of cannabis to achieve high THC effects for certain patients. Fleta and Mike emphasise the importance of therapy in every treatment plan, whether it be through coaching, encouragement, or support in using medication effectively. They stress that therapy is a key component in personalised treatment, aiming to make symptoms more manageable rather than curing the underlying disease.

The discussion then shifts to psychedelic-assisted therapy, particularly MDMA-assisted therapy for PTSD. Fleta and Mike share remarkable results from studies showing significant improvement in patients' symptoms and even full remission from PTSD criteria. They explain the need for a team of therapists, doctors, special facilities, and tightly regulated medications to deliver these treatments effectively.

Fleta and Mike delve into the history of psychedelics and their therapeutic potential, highlighting the ongoing research and regulatory changes happening globally. They discuss the challenges and opportunities of providing access to these treatments in Australia, where there is a limited number of trained psychiatrists and specialised clinics. Despite the obstacles, they remain optimistic about the potential impact of psychedelics on mental health care.

We’d love your feedback on this podcast series, please take a moment to complete this short survey: ​​https://forms.office.com/r/W0R1cEtMjh

The LSWA podcast is brought to you by Life Sciences WA. Stay updated on LSWA and connect by visiting our website, https://www.lifescienceswa.com.au.

This show is a proud member of the Talking HealthTech Podcast Network - the premier audio destination for cutting-edge insights and thought leadership in healthcare delivery, innovation, digital health, healthcare ICT, and commercialisation. Learn more at www.talkinghealthtech.com/podcast/network.

  continue reading

14 episodes

Artwork
iconShare
 
Manage episode 397108888 series 3427899
Content provided by Life Sciences WA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Life Sciences WA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of the LSWA podcast, host Tracey Wilkinson interviews Fleta Solomon and Michael Winlo, two experts in the field of psychedelic-assisted therapy and medical cannabis. They discuss the potential of these treatments to revolutionise mental health care and provide a more holistic approach to patient care.

The conversation begins with a focus on the use of cannabis to achieve high THC effects for certain patients. Fleta and Mike emphasise the importance of therapy in every treatment plan, whether it be through coaching, encouragement, or support in using medication effectively. They stress that therapy is a key component in personalised treatment, aiming to make symptoms more manageable rather than curing the underlying disease.

The discussion then shifts to psychedelic-assisted therapy, particularly MDMA-assisted therapy for PTSD. Fleta and Mike share remarkable results from studies showing significant improvement in patients' symptoms and even full remission from PTSD criteria. They explain the need for a team of therapists, doctors, special facilities, and tightly regulated medications to deliver these treatments effectively.

Fleta and Mike delve into the history of psychedelics and their therapeutic potential, highlighting the ongoing research and regulatory changes happening globally. They discuss the challenges and opportunities of providing access to these treatments in Australia, where there is a limited number of trained psychiatrists and specialised clinics. Despite the obstacles, they remain optimistic about the potential impact of psychedelics on mental health care.

We’d love your feedback on this podcast series, please take a moment to complete this short survey: ​​https://forms.office.com/r/W0R1cEtMjh

The LSWA podcast is brought to you by Life Sciences WA. Stay updated on LSWA and connect by visiting our website, https://www.lifescienceswa.com.au.

This show is a proud member of the Talking HealthTech Podcast Network - the premier audio destination for cutting-edge insights and thought leadership in healthcare delivery, innovation, digital health, healthcare ICT, and commercialisation. Learn more at www.talkinghealthtech.com/podcast/network.

  continue reading

14 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide